| Expression pattern: |
DN |
| Associated gene: |
CDKN1A, p21, AGO2 |
| Associated microRNA: |
miR-370-3p |
| Biological function: |
Induces cellular senescence and G1 phase arrest, inhibits gastric cancer cell proliferation and migration, and suppresses gastric cancer progression in vivo. |
| Molecular mechanism: |
circCHAF1A acts as a cytoplasmic ceRNA that sponges miR-370-3p, upregulates CDKN1A/p21, and enhances CDKN1A/p21 mRNA stability, thereby promoting cellular senescence and suppressing gastric cancer progression. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); cell cycle (inhibits); ceRNA regulation (other); mRNA stability (promotes); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Transwell Assay; IF (Immunofluorescence); Western Blot; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circCHAF1A expression is associated with poor prognosis, advanced TNM stage, and lymph node metastasis in gastric cancer; circCHAF1A may serve as a biomarker for disease progression and a therapeutic target. |
| Description: |
circCHAF1A is a CHAF1A-derived human circRNA that is downregulated in gastric cancer tissues and cell lines. It suppresses gastric cancer progression by sponging miR-370-3p, increasing CDKN1A/p21 expression and mRNA stability, inducing cellular senescence and G1 arrest, and inhibiting proliferation and migration. Clinically, low circCHAF1A expression is linked to poor prognosis, TNM stage, and lymph node metastasis. |
| Confidence score: |
0.8684 |